CureDuchenne Ventures

CureDuchenne Ventures

CureDuchenne Ventures’ impact fund deploys donor dollars to fund Duchenne muscular dystrophy treatments with the singular vision of funding a cure for the entire Duchenne community.

CureDuchenne Ventures is a Newport Beach, California based venture capital firm. They are the investment arm of CureDuchenne, a nonprofit dedicated to curing Duchenne muscular dystrophy. Their investments are focused on finding treatments and a cure for Duchenne muscular dystrophy.

CureDuchenne Ventures offers investment ranging from $50,000 to $5 million dependent on project needs. They also offer partnership and collaborations with the FDA, pharmaceutical and biotechnology industry. Their funding comes through in either grants, loans, or equity financing.

Investment

CureDuchenne Ventures has invested in Bamboo Therapeutics, Capricor Therapeutics, Collaborative Trajectory Analysis Project, Exonics Therapeutics, MyoTherix, Nationwide Children's, Biomarin, PTC Therapeutics, Sarepta Therapeutics, RASRx, TRiNDS, Baebies, 4DMT, Avidity Biosciences, ZappRx, and ReveraGen.

Timeline

Funded Companies

Company
Description
Industry
Website
Location
Avidity Biosciences

Avidity Biosciences is a La Jolla-based company.

4D Molecular Therapeutics designs, develops and commercializes products for gene therapy.

Edgewise Therapeutics is a Boulder, Colorado-based drug discovery company.

Shape Therapeutics is a Seattle-based company.

5 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
April 22, 2020
BioSpace
Myosana Therapeutics, Inc. Raises Up To $1M from CureDuchenne Ventures - read this article along with other careers information, tips and advice on BioSpace

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.